Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares of Stock

Posted by George Bondi on Aug 21st, 2026

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the sale, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $327,860.34. The trade was a 66.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

On Wednesday, June 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46.

Palvella Therapeutics Trading Down 4.9%

NASDAQ PVLA opened at $142.58 on Friday. The stock’s 50 day moving average is $141.68 and its two-hundred day moving average is $124.34. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of -29.52 and a beta of -0.17. Palvella Therapeutics, Inc. has a 1-year low of $48.65 and a 1-year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, analysts predict that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Institutional Investors Weigh In On Palvella Therapeutics

A number of large investors have recently bought and sold shares of PVLA. The Manufacturers Life Insurance Company lifted its position in Palvella Therapeutics by 688.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock worth $2,232,000 after buying an additional 15,637 shares in the last quarter. Jennison Associates LLC grew its holdings in Palvella Therapeutics by 262.4% during the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after acquiring an additional 280,573 shares during the last quarter. Emerald Mutual Fund Advisers Trust acquired a new stake in Palvella Therapeutics in the 1st quarter valued at about $13,190,000. WCM Investment Management LLC acquired a new stake in Palvella Therapeutics in the 1st quarter valued at about $4,982,000. Finally, Profund Advisors LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $608,000. 40.11% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on PVLA shares. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Finally, HC Wainwright reissued a “buy” rating and set a $270.00 price target on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $209.14.

View Our Latest Analysis on Palvella Therapeutics

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.